Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology.“Although the therapeutic arsenal of CD has increased considerably in 5 years with the availability of monoclonal antibodies targeting [interleukin-12/interleukin-23] (ustekinumab) or leukocyte trafficking (vedolizumab), the response rates of these new drugs are not higher than those obtained with [infliximab], especially because the effectiveness of the biologics decreasesRead More